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Abstract
Background/Aims: Contrast induced acute kidney injury (CI-AKI) remains a serious 
complication of contrast media enhanced procedures like coronary angiography. There is still 
a lack of established biomarkers that help to identify patients at high risk for short and long-
term complications. The aim of the current study was to evaluate plasma kynurenine as a 
predictive biomarker for CI-AKI and long-term complications, measured by the combined 
endpoint "major adverse kidney events" (MAKE) up to 120 days after CM application. Methods: 
In this prospective cohort study 245 patients undergoing coronary angiography were 
analyzed. Blood samples were obtained at baseline, 24h and 48h after contrast media (CM) 
application to diagnose CI-AKI. Patients were followed for 120 days for adverse clinical events 
including death, the need for dialysis, and a doubling of plasma creatinine. Occurrence of any 
of these events was summarized in the combined endpoint MAKE. Results: Preinterventional 
plasma kynurenine was not associated with CI-AKI. Patients who later developed MAKE 
displayed significantly increased preinterventional plasma kynurenine levels (p<0.0001). ROC 
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p<0.0001). The optimal cutoff was found at ≥3.5 μmol/L. Using this cutoff, the Kaplan-
Meier estimator demonstrated that concentrations of plasma kynurenine ≥3.5 μmol/L were 
significantly associated with a higher prevalence of MAKE until follow up (p<0.0001). This 
association remained significant in multivariate Cox regression models adjusted for relevant 
factors of long-term renal outcome. Conclusion: Preinterventional plasma kynurenine might 
serve as a highly predictive biomarker for MAKE up to 120 days after coronary angiography.
© 2017 The Author(s)
Published by S. Karger AG, Basel
IntroductionOver 80 million procedures using iodinated contrast media (CM) are performed annually [1]. Contrast-induced acute kidney injury (CI-AKI) is a prevalent complication of such CM enhanced examinations and procedures [1]. The Contrast Media Safety Committee 
of the European Society of Urogenital Radiology (ESUR) defines CI-AKI as an increase in 
plasma creatinine of at least 25 % or 44 μmol/l within 3 days after CM administration in the absence of an alternative etiology [2]. CI-AKI occurs in up to 5% of hospitalized patients 
with normal renal function prior to CM administration, but the prevalence dramatically 
increases to 20-30% in high risk patients such as patient with diabetes, congestive heart 
failure or preexisting renal insufficiency [3, 4]. However, the true prevalence of CI-AKI might 
be higher, as CI-AKI is often clinically undetected because patients can be asymptomatic [4]. 
Furthermore, due to technical improvements, many patients undergoing CM interventions 
are likely to be discharged within 24 hours, complicating an assessment of plasma 
creatinine concentrations for more than 24 hours after CM exposure [5]. Most patients who experienced CI-AKI usually display a partial or complete recovery of kidney function by the 
time of hospital discharge [6], but several recent cohort studies have shown that CI-AKI is 
associated with long-term loss of kidney function, cardiovascular events, and death [6-8]. There is increasing consensus that ultimate clinical outcomes should be moved in the focus of studies investigating contrast media associated nephrotoxicity [9]. The acute endpoint 
CI-AKI itself, characterized by changes in plasma creatinine or urine excretion over set time 
intervals, merely indicates transient pathophysiology, which may or may not eventually 
result in a significant clinical outcome [9]. This is underlined by data, indicating that also 
subclinical CI-AKI is associated with increased long-term mortality [10, 11]. Until now, there 
is no established specific biomarker that helps identifying patient subgroups which are at an increased risk for long-term sequelae of CM interventions.
Kynurenine is the first stable metabolite of the least-abundant essential amino acid, 
L-tryptophan, which plays an important role in protein synthesis and functions as a biochemical precursor for several other important biomolecules [12]. The catabolism of 
tryptophan to kynurenine is mediated by indoleamine 2,3-dioxygenase (IDO) and tryptophan 
2,3-dioxygenase [12, 13]. The expression of IDO is induced by inflammatory cytokines, in 
particular by interferon- γ and to a lesser extent by tumor necrosis factor-α [14-16]. Current 
literature suggests that an activated IDO induces homeostatic mechanisms against excessive 
immune reactions, promotes immune tolerance and elicits anti-inflammatory effects [14]. 
IDO is activated in various diseases, leading to decreasing tryptophan and increasing 
kynurenine blood levels [17]. Moreover, chronic systemic low-grade inflammation enhances 
IDO activation [14]. Chronic kidney disease (CKD) is accompanied by immune dysregulation 
and more recent studies have shown that the kynurenine pathway is associated with 
chronic kidney disease (CKD) [12, 15, 18-20]. It was demonstrated that CKD patients 
display increased kynurenine plasma levels [19-21]. Furthermore, it was shown in animal 
and cell culture experiments that kynurenine does not just accumulate in CKD patients 
due to impaired kidney function, but that the kynurenine pathway might be involved in the 
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The aim of the current study was to evaluate whether preinterventional plasma 
kynurenine concentrations can predict short and medium-term outcome in patients with preexisting renal risk factors subjected to CM application due to coronary angiography.
Materials and Methods
Study population and protocol
This prospective cohort study, performed from January 2010 to December 2011, was approved by 
the authors' institutional review board of the university hospital Charité, Berlin, Germany. All clinical 
investigations were conducted according to the principles expressed in the Declaration of Helsinki. 245 
patients with renal impairment (baseline creatinine > 1.1 mg/dL) or diabetes mellitus (diagnosed before 
study begin or HbA1c > 46 mmol/mol) undergoing coronary angiography were included. All patients 
without any present inclusion criteria, patients with terminal kidney disease and patients who did not sign 
the informative consent were excluded from the study. Additionally, patients who did not or were not able 
to provide their agreement to participate were excluded. Individual patient risk for CI-AKI was assessed 
and calculated based on Mehran contrast nephropathy risk score, which calculates an individual patient risk score for CI-AKI based on readily available information [24]. The variables included in this calculation 
are patient-related characteristics such as an age over 75 years, diabetes mellitus, congestive heart failure, 
hypotension, anemia, chronic kidney disease and procedure-related characteristics like the use of elective intraaortic baloon pumps or increasing volumes of contrast media [24]. According to the number of present 
risk factors the total score can be ranked into four groups: low CI-AKI risk (≤ 5), moderate CI-AKI risk (6 - 
10), high CI-AKI risk (10-15) and very high CI-AKI risk (≥ 16) [24].
Blood was collected before, 24h, and 48h after CM application, if possible. In 22 patients we were not able to obtain plasma after CM application for a reliable assessment of CI-AKI based on changes in plasma 
creatinine. Patients were followed for 120 days. Patient treatment was not influenced in any case by this 
study. All patients received tri-iodonated non-ionic low-osmolar iobitridol (XENETIX® 350, Guerbet GmbH, 
Sulzbach/Taunus, Germany) in a concentration of 350 mg iodine/mL as contrast medium. Patients at high 
risk for CI-AKI [2] were subjected to preventive measures, which included hydration before or after CM 
application, N-acetyl-L-cysteine (ACC), Ca-antagonist, and theophyllin treatment.
Sample treatment and measurement
After collection, EDTA-blood samples were centrifuged for 5 min at 3000 rpm to obtain plasma. Plasma 
samples were then frozen and stored at −80 °C. For the measurement of creatinine the Jaffé method was 
used. Glomerular filtration rate was estimated by the modification of diet in renal disease (MDRD) formula. 
Cystatin C was measured employing an immunonephelometric method using polystyrene particles coated 
with human cystatin C specific antibodies (Siemens Healthcare Diagnostics Products GmbH, Marburg, 
Germany). For the measurement of kynurenine an ELISA assay was used (IDK® Kynurenine ELISA K 7728, 
Immundiagnostik AG, Bensheim, Germany). The lower detection limit of the assay is 0.12 µmol/L with a 
limit of quantification of 0.18 µmol/L. Intra-assay coefficients of variation range between 6.2 and 7.6%. Both 
patients and doctors were blinded to measured kynurenine levels.
Definition of endpoints
CI-AKI was defined as an increase of plasma creatinine by 25% or 0.5 mg/dL from baseline within 
48 h. Death was described as the subsumption of death of all causes. The endpoint dialysis was defined as 
every dialysis in 120 days following CM exposure. The endpoint doubling of plasma creatinine refers to a 
100% increase from baseline plasma creatinine levels. The primary composite endpoint of this study was 
the occurrence of major adverse kidney events (MAKE) until follow up to 120 days after CM administration. 
In the vast majority of cases (n=233) follow up was organized by interviewing the respective patient, in 
the remaining cases close relatives or the family physician was questioned. If available, medical reports 
were obtained. MAKE was defined as one of the following events: death, dialysis or a doubling of plasma 
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Statistical analyses
Data were analyzed using 
SPSS version 20.0 (SPSS, Inc, 
Chicago, IL, USA). Figures were 
compiled with Graphpad Prism 
5 (GraphPad Software Inc., La 
Jolla, California, USA) or SPSS 
version 20.0 (SPSS, Inc, Chicago, 
IL, USA). All values are given as mean ± standard deviation 
(SD). Depending on group-
specific normal distribution either unpaired t-test or the 
Mann-Whitney U test was used 
to compare two groups. For the comparison of categorical 
variable distribution, the 
chi-squared test was used. 
To assess specificity and 
sensitivity, receiver operating characteristic (ROC) curves 
were calculated. Representing 
the best cutoff value, the point of the curve closest to the upper left corner of the coordinate system (sensitivity 
and specificity equal 1), 
was calculated and used to transform a continuous parameter into a binary endpoint [26]. To analyze 
group specific occurrence of 
events over time, Kaplan-Meier 
curves were calculated and 
tested for statistical significant differences using the Log-rank Mantel-Cox test. To adjust for 
Table 1. Descriptive statistics of the analyzed cohort (continuous data 
are given as mean ± SD)
possible confounding, multivariate Cox regression analysis was performed. Probability values <0.05 were 
considered significant. The authors had full access to the data and take full responsibility for their integrity.
Results
A total of 245 patients undergoing coronary angiography were statistically analyzed. Ta-
ble 1 shows descriptive statistics of the cohort. The mean age of the cohort was 68.7 ± 9.7 years, 
21.6% (53) of all patients were female, 78.4% (192) were male, 98.8% (242) had a caucasian 
ethnic background, 1.2% (3) were non-caucasian, 63.7% (156) were former and 16.3% (40) 
were current smokers. The average body mass index (BMI) was 28.9 ± 5.5 kg/m², mean HbA1c 
concentration was 50 ± 12 mmol/mol with 52.2% (128) of all patients being diabetics. Of all 
patients, 89.9% (220) suffered from renal insufficiency. Hypertension was present in 89.0% 
(218), 75.1% (184) of all patients suffered from coronary artery disease, 17.6% (43) displayed 
peripheral artery disease, 76.7 (188) presented with artery occlusive disease, 27.3% (67) 
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were 1.17 ± 0.49 mg/L. The average GFR was 64.02 ± 21.63ml/min/1.73 m2. Following CM 
application, 8.5% (19) developed CI-AKI. Over the course of the study, 4.9% (12) had to under-
go dialysis, 3.7% (9) of patients died and 0.4% (1) displayed a doubling of plasma creatinine. 
Taken together, 6.9% (17) reached the combined endpoint MAKE.
Table 2 shows preinterventional plasma kynurenine concentrations in patient subgroups 
with or without the occurrence of clinical events. CI-AKI and doubling of plasma creatinine 
until follow up was not associated with any changes in plasma kynurenine concentrations. 
However, patients who died, had to receive dialysis, or developed MAKE until follow up, 
displayed significantly elevated plasma kynurenine levels.The predictive value of preinterventional kynurenine in regards to the primary end-
point of this study, MAKE, was calculated by the area under the receiver operating charac-
teristic curve (ROC-AUC), which is shown in Fig. 2. Preinterventional kynurenine was very 
accurate in predicting MAKE (AUC=0.838; 95% C.I.= 0.738-0.939; p=3.3 x 10-6). The opti-
Table 2. Baseline plasma kynurenine (KYN) concentrations (μmol/l) 
according to clinical events, *) Elevation of plasma creatinine by 25% or 
0,5mg/dl from baseline in 48h; †) Death until follow up; ‡) Dialysis until 
follow up; §) Doubling of plasma creatinine until follow up; ||) Combined endpoint "major adverse kidney events" (MAKE): death or dialysis or 
doubling of plasma creatinine until follow up
6.5, 50.2% (123) displayed a 
low, 29.8% (73) a moderate, 
16.3 (40) a high and 3.7% (9) a very high risk for CI-AKI. Regarding patient med-
ication, 62.0% (152) were 
treated with statins, 33.1% (81) received angiotensin II 
receptor blockers (ARBs), 57.6% (141) took angioten-sin converting enzyme (ACE) 
inhibitors, and 64.5% (158) 
were treated with diuretics. 
In 94.7% (232) of patients elective coronary angiogra-
phy was performed, 5.3% 
(13) required an emergency coronary angiography. Mean administered CM volume 
was 115.3 ± 57.0 mL. Regard-ing prophylactic measures during coronary angiogra-
phy, 55.1% (135) received hydration before or after CM 
application, 48.2% (118) 
were treated with N-acetyl-
L-cysteine (ACC), 26.1 (64) 
received Ca-antagonists, 
and 1.2% (3) received the-
ophyllin. Baseline plasma kynurenine concentrations 
were 3.18 ± 1.03 µmol/L. The distribution of measured baseline plasma kynurenine 
concentrations is shown in 
Fig. 1. Baseline creatinine 
concentrations were 1.27 
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(p<0.0001). Correspondingly, higher preinterventional kynurenine was associated with a 
higher prevalence for hydration before or after CM application (p=0.0001), and more ACC 
prophylaxis (p<0.0001). Furthermore preinterventional plasma kynurenine concentra-
tions ≥ 3.5 μmol/L were associated with a higher prevalence for dialysis (p<0.0001), death 
(p=0.004) and the combined endpoint MAKE (p<0.0001).
Table 4 displays patient characteristics according to the occurrence of MAKE until follow 
up. Patients with MAKE until follow up had significantly higher baseline plasma kynurenine, 
cystatin C and creatinine concentrations (all p<0.0001) and a lower baseline GFR (p<0.0001). 
Patients who experienced MAKE also had a higher prevalence for congestive heart failure 
(p=0.003) and anemia (p=0.003) and more often were smokers (p=0.028). MAKE was associ-
ated with a higher renal risk score (p=0.0002) and a higher prevalence for high and very high 
CI-AKI risk (p=0.0005). Furthermore, patients who experienced MAKE more often underwent an emergency coronary angiography (p=0.019).
Employing the Kaplan-Meier estimator, differences in the occurrence of MAKE until the 
follow up according to plasma kynurenine < 3.5 μmol/L and ≥ 3.5 μmol/L were analyzed. 
Plasma levels of kynurenine ≥ 3.5 μmol/L were significantly associated with a higher prevalence 
of MAKE until follow up (Log-rank Mantel-Cox test; chi-squared=31.59; p=1.9 x 10-8; see Fig. 
3). Multivariate Cox-regression models using established risk factors for MAKE [27], that were 
significantly different in the observed cohort stratified into no MAKE or MAKE (Table 3), were 
calculated to demonstrate an independent association between plasma kynurenine ≥ 3.5 
μmol/L and an elevated risk for MAKE (Table 5). Model A used baseline GFR, congestive heart 
failure, anemia, age, contrast media volume, elective or emergency coronary angiography, 
and current smoking status as covariates (chi-squared=33.250, p=0.00002) . Adding plasma 
kynurenine as categorical variable (KYN < 3.5 μmol/L or ≥ 3.5 μmol/L) in model B to the same 
covariates as used in model A improved the overall strength of the model (chi-squared=48.679, 
p=7.33 x 10-8) and rendered the association between GFR and MAKE insignificant. In model 
C plasma kynurenine was applied to the same covariates as used in model A as a continuous 
variable, resulting in a similar model strength as observed in Model B. (chi-squared=47.171, p=1.42 x 10-7). As there is considerate evidence in literature that CI-AKI also impacts long-term 
outcome [6-8], model D was furthermore adjusted for the occurrence of CI-AKI. An addition 
of CI-AKI to the covariates only mildly affected the independent association between plasma kynurenine and MAKE.
Fig. 2. ROC curve of baseline plasma kynurenine (KYN) 
concentrations as test variable and MAKE until follow up as state variable.mal cutoff value for kynurenine was ≥ 3.5 μmol/L. Table 3 shows descrip-tive statistics of the cohort grouped 
into patients with plasma kynurenine 
concentrations < 3.5 μmol/L and ≥ 
3.5 μmol/L. Significant differences 
in patients with plasma kynurenine 
concentrations ≥ 3.5 μmol/L were a 
higher age (p=0.019), higher base-line concentrations of creatinine and 
cystatin C (both p<0.0001), a lower 
GFR (p<0.0001), a higher prevalence 
for preexisting renal insufficiency 
(p=0.036), congestive heart failure 
(p=0.001), and anemia (p=0.003). Pa-
tients with higher preinterventional 
plasma kynurenine were more often 
taking diuretics (p=0.006), displayed 
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Discussion
To the best of our knowledge, this is the first study that investigated kynurenine in the context of renal outcomes after CM application due to coronary angiography. The patient 
cohort analyzed in this study can be considered representative, featuring similar clinical 
characteristics and risk factor frequencies as observed in larger studies [5, 24]. Patients 
who developed MAKE up to 120 days after CM administration displayed significantly elevated preinterventional plasma kynurenine levels. ROC analysis demonstrated that 
preinterventional plasma kynurenine levels are highly predictive of MAKE, with an optimal 
cutoff of ≥3.5 μmol/L. Employing the Kaplan-Meier estimator, revealed that patients with 
plasma kynurenine ≥3.5 μmol/L have a strongly increased risk of MAKE (death, need for 
dialysis, doubling of plasma creatinine). Multivariate Cox regression models demonstrated 
Table 3. Descriptive statistics of patients grouped according to baseline kynurenine (KYN) 
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Fig. 3. Kaplan-Meier anal-
ysis of MAKE until follow 
up in patients with baseline 
kynurenine (KYN) concen-
trations < 3.5 µmol/L and ≥ 
3.5 µmol/L. Log rank (Man-
tel Cox) test, chi-squared = 
31.59; p<0.0001.
Table 4. Descriptive statistics of patients grouped according to the occurrence of MAKE until 
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that this association is independent of other important risk factors. Taken together, results 
of this study show an independent association between baseline plasma kynurenine levels and the occurrence of MAKE up to 120 days after contrast media exposure due to coronary 
angiography in a population with moderate risk for CI-AKI.
Given the multifaceted contribution of the kynurenine pathway in fundamental 
biological processes, impacting on inflammation, oxidative stress, and endothelial function, 
Table 5. Multivariate Cox regression analyzing the association between preintervetional serum kynurenine 
and MAKE, The dependent variable is MAKE up to 120 days after CM intervention. Model A: baseline GFR, 
congestive heart failure, anemia, age, contrast media volume, elective or emergency coronary angiography 
(CA), and current smoking status. Model B: same covariates as model A plus plasma kynurenine as categor-
ical variable (KYN < 3.5 μmol/L or ≥ 3.5 μmol/L). Model C: same covariates as model A plus plasma kynure-
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current literature suggests an involvement of kynurenine in both acute and chronic kidney 
disease [18, 28]. Previous studies have demonstrated that metabolites of the kynurenine 
pathway are elevated in CKD animal models as well as in CKD patients [21, 29], and 
kynurenine metabolites were shown to increase parallely to decreasing renal function [29, 
30]. Moreover, studies show that plasma kynurenine is positively associated with plasma 
markers of chronic inflammation in CKD patients [19, 20]. Results of this study showed 
that patients with baseline plasma kynurenine levels ≥ 3.5 µmol/L also had a significantly 
reduced GFR and elevated levels of plasma creatinine and cystatin C, underlining that these 
patients suffered from a preexisting impaired renal function. However, plasma kynurenine 
was still significantly associated with MAKE after adjusting for glomerular filtration rate, 
age, congestive heart failure, anemia, contrast media volume, and CI-AKI — all risk factors 
evinced in previous larger studies [24]. Also, elective or emergency coronary angiography 
and smoking — both factors that were significantly increased in MAKE patients —  did not 
strongly affect the independent association between elevated plasma kynurenine and MAKE.
An increased activity of tryptophan-metabolizing enzymes due to inflammatory stimuli 
is currently accepted as the main mechanism behind elevated kynurenine levels in CKD 
[12, 18, 20, 31]. Additionally an attenuated renal excretion of kynurenine is suggested by 
the literature [18, 21]. Until now it is not clear if elevated kynurenine levels are causally 
involved in the pathogenesis of kidney disease. Interestingly, kynurenine formamidase 
knock out animals display a significant increase of metabolites of the kynurenine 
pathway, concomitant to a gradual deterioration of kidney function [22]. Furthermore, 
it was demonstrated in mesangial cell culture experiments that kynurenine stimulates 
profibrotic gene expression [23]. The authors concluded that kynurenine metabolites 
might be associated with the progression of glomerular fibrosis and renal failure [23]. Such observations indicate a possible pathological role of accumulated kynurenine metabolites in the progression of renal failure and might also serve as one possible explanation for the 
association between elevated plasma kynurenine and an increased risk of MAKE in this study 
[23]. This notion is to some extent supported by results of a large general population-based 
longitudinal study performed over the duration of 7 years. It was shown that the baseline 
kynurenine-to-tryptophane ratio is associated with kidney function decline and CKD 
incidence years later. However, differently from the current study, no significant association 
was observed when assessing plasma kynurenine levels solely. Yet, this might have been related to the relatively healthy study population and the different study setting. Alterations 
of either substrate or metabolite alone could have been too minor to observe an effect, but 
the impact of this factor was not strengthened by calculating a ratio out of the two oppositely 
changing components [31].
Results of this study show that, regardless of the underlying mechanism, kynurenine might serve as a preinterventional highly predictive biomarker for MAKE up to 120 days 
after coronary angiography. However, baseline kynurenine was not associated with CI-
AKI. Additionally, there was no significant association between CI-AKI and MAKE, which has already been observed by other studies [10]. These missing associations might be 
explained by the same underlying reasons. The frequency of CI-AKI in the current study was 
lower than in other studies, presumably due to under-diagnosis [5]. Blood samples were 
obtained up to 48h after CM application, but CI-AKI might still have developed after this time 
threshold [5]. Moreover, diagnostic classifications like ESUR define CI-AKI as an impairment 
of glomerular function, usually measured by the current gold standard surrogate parameter, 
plasma creatinine [32, 33]. It is well accepted that the diagnostic properties of plasma 
creatinine assessment has limitations, as it displays a delayed rise in response to an acute 
renal failure triggering insult and also lacks specificity due to extrarenal influences on 
plasma concentrations [5, 9]. Furthermore, current definitions neglect a hallmark of acute 
renal failure and in particular CI-AKI, which is an impairment of tubular function due to 
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biomarker/negative for creatinine) might be at an increased risk for short- and long-term 
morbidity and mortality [11]. The unexpected missing association between CI-AKI and 
MAKE, observed in the current study, supports these data. In this context, recent reviews of clinical studies investigating acute renal impairment proposed that employing a renal 
composite endpoint like MAKE could be used to better define patients with a meaningful 
poor outcome [37].Findings of the current study might have relevant clinical implications. Calculating a threshold for kynurenine using the kynurenine ROC curve for MAKE resulted in a cut-off 
concentration for kynurenine of ≥ 3.5 μmol/L to identify patients at risk for MAKE after coronary angiography. This might be clinically very important information for patient’s 
management, especially as kynurenine can be assessed prior to a CM enhanced procedure. Patients at high risk for MAKE based on kynurenine concentrations before intervention may 
need a much closer follow-up as compared to patients with low MAKE risk. Preinterventional 
kynurenine could also be used in decision making in high risk populations with uncertain 
beneficial effects of a percutaneous intervention, e.g. diabetic patients with multivessel 
coronary artery disease [38]. Thus, kynurenine could be a tool for personalized patient care management before and after coronary angiography. Future studies should investigate 
whether or not pharmacological alterations of kynurenine concentrations prior to coronary 
angiography may alter the MAKE risk, in other words, whether or not kynurenine is just a risk biomarker or a risk factor for MAKE.
Study limitationsThe main limitation of the current study is the lack of an independent replication cohort. 
Thus, findings of the current study have to be replicated in future studies. Another limitation 
of the current study is that plasma and urine samples were only obtained only until 48h after 
CM application. As current guidelines define CI-AKI as an increase in plasma creatinine by at 
least 25 % within 3 days after CM administration, CI-AKI might have been under-diagnosed. 
Furthermore, the kynurenine pathway could have been analyzed more in-depth, putatively 
drawing a more detailed picture of the involvement of kynurenine and other tryptophan metabolites in CI-AKI and MAKE.
Conclusion
In patients with moderately impaired renal function, high preinterventional plasma 
kynurenine levels were associated with a worse medium-term outcome after contrast media 
enhanced coronary angiography. Importantly, this association was independent of relevant risk factors of medium- and long-term renal morbidity and mortality including estimates 
of glomerular function. Further investigations are needed to validate the additional benefit of assessing preinterventional plasma kynurenine in predicting medium- and long-term renal outcome after contrast media enhanced procedures. Current evidence suggests that the concomitant measurement of several different renal biomarkers might help stratifying 
patients into high and low risk groups after CM enhanced interventions.
Abbreviations
CM - contrast media; CI-AKI - contrast induced acute kidney injury; ESUR - European 
Society of Urogenital Radiology; KYN - kynurenine; MAKE - major adverse kidney events



















   
   
   
   
   
   
   
   
   




















 Kidney Blood Press Res 2017;42:244-256
DOI: 10.1159/000477222
Published online: May 16, 2017
© 2017 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 255
Reichetzeder et al.: Kynurenine Predicts Outcome after Contrast Media Exposure
References
1  Silver SA, Shah PM, Chertow GM, Harel S, Wald R, Harel Z: Risk prediction models for contrast induced 
nephropathy: systematic review. BMJ 2015;351:h4395. 
2  Stacul F, van der Molen AJ, Reimer P, Webb JAW, Thomsen HS, Morcos SK, Almén T, Aspelin P, Bellin M-F, 
Clement O, Heinz-Peer G, Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR): Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur 
Radiol 2011;21:2527-2541. 
3  Curtis LM, Agarwal A: Hope for contrast-induced acute kidney injury. Kidney Int 2007;72:907-909. 
4  Golshahi J, Nasri H, Gharipour M: Contrast-induced nephropathy; A literature review. J Nephropathol 
2014;3:51-56. 
5  Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G: Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or 
percutaneous intervention. Eur J Prev Cardiol 2015;23:931-937. 
6  Pannu N, James M, Hemmelgarn B, Klarenbach S, Alberta Kidney Disease Network: Association between 
AKI, recovery of renal function, and long-term outcomes after hospital discharge. Clin J Am Soc Nephrol 
2013;8:194-202. 
7  James MT, Wald R: AKI: not just a short-term problem? Clin J Am Soc Nephrol 2014;9:435-436. 
8  Sigterman TA, Krasznai AG, Snoeijs MG, Heijboer R, Schurink GWH, Bouwman LH: Contrast Induced 
Nephropathy and Long-term Renal Decline After Percutaneous Transluminal Angioplasty for Symptomatic 
Peripheral Arterial Disease. Eur J Vasc Endovasc Surg 2016;51:386-393. 
9  Billings FT, Shaw AD: Clinical Trial Endpoints in Acute Kidney Injury. Nephron Clin Pract 2014;127:89-93. 
10  Weisbord SD, Palevsky PM: Contrast-induced acute kidney injury: short- and long-term implications. Semin 
Nephrol 2011;31:300-309. 
11  Huen SC, Parikh CR: Molecular phenotyping of clinical AKI with novel urinary biomarkers. Am J Physiol Ren 
Physiol 2015;309:F406-F413. 
12  Zhao J: Simultaneous determination of plasma creatinine, uric acid, kynurenine and tryptophan by high-performance liquid chromatography: method validation and in application to the assessment of renal 
function. Biomed Chromatogr 2015;29:410-415. 
13  Saito K, Fujigaki S, Heyes MP, Shibata K, Takemura M, Fujii H, Wada H, Noma A, Seishima M: Mechanism 
of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am J Physiol Renal Physiol 
2000;279:F565-572. 
14  Hocher B, Adamski J: Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol 
2017;13:269-284.  
15  Kato A, Suzuki Y, Suda T, Suzuki M, Fujie M, Takita T, Furuhashi M, Maruyama Y, Chida K, Hishida A: 
Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in 
hemodialysis patients. Hemodial Int 2010;14:418-424. 
16  Sulo G, Vollset SE, Nygård O, Midttun Ø, Ueland PM, Eussen SJPM, Pedersen ER, Tell GS: Neopterin and 
kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. 
Int J Cardiol 2013;168:1435-1440. 
17  Ristagno G, Latini R, Vaahersalo J, Masson S, Kurola J, Varpula T, Lucchetti J, Fracasso C, Guiso G, Montanelli 
A, Barlera S, Gobbi M, Tiainen M, Pettilä V, Skrifvars MB: Early Activation of the Kynurenine Pathway Predicts 
Early Death and Long-term Outcome in Patients Resuscitated From Out-of-Hospital Cardiac Arrest. J Am 
Heart Assoc 2014;3:e001094. 
Acknowledgements
KK is the CEO of Neuroimmun AG, the manufacturer of the kynurenin ELISA Kit used 
to measure serum kynurenin in the current study (IDK® Kynurenine ELISA K 7728). AK is 



















   
   
   
   
   
   
   
   
   




















 Kidney Blood Press Res 2017;42:244-256
DOI: 10.1159/000477222
Published online: May 16, 2017
© 2017 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 256
Reichetzeder et al.: Kynurenine Predicts Outcome after Contrast Media Exposure
18  Zhao J: Plasma kynurenic acid/tryptophan ratio: a sensitive and reliable biomarker for the assessment of 
renal function. Ren Fail 2013;35:648-653. 
19  Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D: The kynurenines are associated with oxidative stress, 
inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. 
Atherosclerosis 2009;204:309-314. 
20  Schefold JC, Zeden J-P, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk H-D, Schuett C, Reinke P: 
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in 
patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. 
Nephrol Dial Transplant 2009;24:1901-1908. 
21  Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W: Accumulation of toxic products degradation of 
kynurenine in hemodialyzed patients. Int Urol Nephrol 2001;33:399-404. 
22  Dobrovolsky VN, Bowyer JF, Pabarcus MK, Heflich RH, Williams LD, Doerge DR, Arvidsson B, Bergquist J, 
Casida JE: Effect of arylformamidase (kynurenine formamidase) gene inactivation in mice on enzymatic 
activity, kynurenine pathway metabolites and phenotype. Biochim Biophys Acta 2005;1724:163-172. 
23  Yoshimura H, Sakai T, Kuwahara Y, Ito M, Tsuritani K, Hirasawa Y, Nagamatsu T: Effects of kynurenine 
metabolites on mesangial cell proliferation and gene expression. Exp Mol Pathol 2009;87:70-75. 
24  Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, 
Leon MB, Dangas G: A simple risk score for prediction of contrast-induced nephropathy after percutaneous 
coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44:1393-1399. 
25  Thongprayoon C, Cheungpasitporn W, Srivali N, Harrison AM, Gunderson TM, Kittanamongkolchai W, 
Greason KL, Kashani KB: AKI after Transcatheter or Surgical Aortic Valve Replacement. J Am Soc Nephrol 
2016;27:1854-1860. 
26  Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter C-M, Slowinski T, Sinha P, Neumayer H-H: 
Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing 
hemodialysis. J Am Soc Nephrol 2003;14:2329-2337. 
27  Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, Kosiborod M, Amin AP, Weintraub WS, 
Curtis JP, Messenger JC, Rumsfeld JS, Spertus JA: Validated contemporary risk model of acute kidney injury in 
patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data 
Registry Cath-PCI Registry. J Am Heart Assoc 2014;3:e001380.
28  Wang Q, Liu D, Song P, Zou M-H: Tryptophan-kynurenine pathway is dysregulated in inflammation, and 
immune activation. Front Biosci Landmark Ed 2015;20:1116-1143. 
29  Pawlak D, Tankiewicz A, Buczko W: Kynurenine and its metabolites in the rat with experimental renal 
insufficiency. J Physiol Pharmacol 2001;52:755-766. 
30  Pawlak D, Tankiewicz A, Matys T, Buczko W: Peripheral distribution of kynurenine metabolites and activity 
of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol 2003;54:175-189. 
31  Goek O-N, Prehn C, Sekula P, Römisch-Margl W, Döring A, Gieger C, Heier M, Koenig W, Wang-Sattler R, Illig T, 
Suhre K, Adamski J, Köttgen A, Meisinger C: Metabolites associate with kidney function decline and incident 
chronic kidney disease in the general population. Nephrol Dial Transplant 2013;28:2131-2138. 
32  Chaykovska L, Heunisch F, von Einem G, Alter ML, Hocher C-F, Tsuprykov O, Dschietzig T, Kretschmer A, 
Hocher B: Urinary Vitamin D Binding Protein and KIM-1 Are Potent New Biomarkers of Major Adverse Renal 
Events in Patients Undergoing Coronary Angiography. PloS One 2016;11:e0145723. 
33  Kellum JA: Diagnostic Criteria for Acute Kidney Injury: Present and Future. Crit Care Clin 2015;31:621-632. 
34  Racusen LC, Solez K: Nephrotoxic tubular and interstitial lesions: morphology and classification. Toxicol 
Pathol 1986;14:45-57. 
35  Endre ZH, Kellum JA, Di Somma S, Doi K, Goldstein SL, Koyner JL, Macedo E, Mehta RL, Murray PT: Differential 
diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the 
tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol 2013;182:30-44. 
36  Ronco C, Stacul F, McCullough PA: Subclinical acute kidney injury (AKI) due to iodine-based contrast media. 
Eur Radiol 2013;23:319-323. 
37  Billings FT, Shaw AD: Clinical trial endpoints in acute kidney injury. Nephron Clin Pract 2014;127:89-93. 



















   
   
   
   
   
   
   
   
   
   
 
13
0.
13
3.
15
2.
82
 - 
8/
31
/2
01
7 
2:
23
:4
5 
PM
